

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

THERAVANCE BIOPHARMA, INC.
(Name of Issuer)

Ordinary Share \$0.00001 Par Value
(Title of Class of Securities)

G8807B106
(CUSIP Number)

31-Dec-22
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be 'filed' for the purpose of Section 18 of the Securities
Exchange Act of 1934 ('Act') or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).

CUSIP No. G8807B106

1. Names of Reporting Persons.

Barclays PLC

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)
(b)

3. SEC Use Only

4. Citizenship or Place of Organization

England, United Kingdom

Number of Shares Beneficially Owned by Each Reporting Person With:	5. Sole Voting Power 3,371,298
	6. Shared Voting Power -0-
	7. Sole Dispositive Power 3,371,298
	8. Shared Dispositive Power -0-

9. Aggregate Amount Beneficially Owned by Each Reporting Person

3,371,298

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)

11. Percent of Class Represented by Amount in Row (9)

5.00%

12. Type of Reporting Person (See Instructions)

HC

CUSIP No. G8807B106

1. Names of Reporting Persons.

Barclays Bank PLC

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) []

(b) []

3. SEC Use Only

4. Citizenship or Place of Organization

England, United Kingdom

Number of Shares Beneficially Owned by Each Reporting Person With:	5. Sole Voting Power 3,402,767
	6. Shared Voting Power -0-
	7. Sole Dispositive Power 3,402,767
	8. Shared Dispositive Power -0-

9. Aggregate Amount Beneficially Owned by Each Reporting Person

3,402,767

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) []

11. Percent of Class Represented by Amount in Row (9)

5.05%

12. Type of Reporting Person (See Instructions)

BD

CUSIP No. G8807B106

1. Names of Reporting Persons.

Barclays Capital Inc.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) []

(b) []

3. SEC Use Only

4. Citizenship or Place of Organization

Connecticut, United States

Number of
Shares
Beneficially
Owned by Each
Reporting
Person With:

5. Sole Voting Power
-3,703

6. Shared Voting Power
-0-

7. Sole Dispositive Power
-3,703

8. Shared Dispositive Power
-0-

9. Aggregate Amount Beneficially Owned by Each Reporting Person

-3,703

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) []

11. Percent of Class Represented by Amount in Row (9)

-0.01%

12. Type of Reporting Person (See Instructions)

BD

CUSIP No. G8807B106

1. Names of Reporting Persons.

Barclays Capital Securities Ltd

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) []
(b) []

3. SEC Use Only

4. Citizenship or Place of Organization

England, United Kingdom

Number of
Shares
Beneficially
Owned by Each
Reporting
Person With:

5. Sole Voting Power
-27,766

6. Shared Voting Power
-0-

7. Sole Dispositive Power
-27,766

8. Shared Dispositive Power
-0-

9. Aggregate Amount Beneficially Owned by Each Reporting Person

-27,766

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) []

11. Percent of Class Represented by Amount in Row (9)

-0.04%

12. Type of Reporting Person (See Instructions)

BD

Item 1.

(a) Name of Issuer:

 THERAVANCE BIOPHARMA, INC.

(b) Address of Issuer's Principal Executive Offices:

 PO Box 309
 Ugland House, South Church Street
 George Town, Grand Cayman, Cayman Islands KY1-1104

Item 2.

(a) Name of Person Filing:

- (1) Barclays PLC
- (2) Barclays Bank PLC
- (3) Barclays Capital Inc.
- (4) Barclays Capital Securities Ltd

(b) Address of Principal Business Office or, if none, Residence:

(1) Barclays PLC
1 Churchill Place,
London, E14 5HP, England

(2) Barclays Bank PLC
1 Churchill Place,
London, E14 5HP, England

(3) Barclays Capital Inc.
745 Seventh Ave
New York, NY 10019

(4) Barclays Capital Securities Ltd
5 The North Colonnade
Canary Wharf
London X0 E14 4BB

(c) Citizenship:

- (1) Barclays PLC: England, United Kingdom
- (2) Barclays Bank PLC: England, United Kingdom
- (3) Barclays Capital Inc.: Connecticut, United States
- (4) Barclays Capital Securities Ltd: England, United Kingdom

(d) Title of Class of Securities:

Ordinary Share \$0.00001 Par Value

(e) CUSIP Number: G8807B106

Item 3. If this statement is filed pursuant to Sub-Section 240.13d-1

(b) or 240.13d-2(b)
or (c), check whether the person filing is a:

- (a) [X] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) [] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) [] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) [] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) [] An investment adviser in accordance with Sub-Section 240.13d-1(b)(1)(ii)(E);
- (f) [] An employee benefit plan or endowment fund in accordance with Sub-Section 240.13d-1(b)(1)(ii)(F);
- (g) [X] A parent holding company or control person in accordance with Sub-Section 240.13d-1(b)(1)(ii)(G);
- (h) [] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) [] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) [X] A non-U.S. institution that is the functional equivalent

of any of the institutions listed in
Rule 240.13d-1 (b) (1) (ii) (A) through (I);
(k) [] Group, in accordance with Sub-Section 240.13d-1 (b) (1) (ii) (J).

Item 4. Ownership.

Provide the following information regarding the
aggregate number and percentage of the class of securities
of the issuer identified in Item 1.

- (a) Amount beneficially owned:
See the response(s) to Item 9 on the attached cover page(s).
- (b) Percent of class:
See the response(s) to Item 11 on the attached cover page(s).
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:
See the response(s) to Item 5 on the
attached cover page(s).
 - (ii) Shared power to vote or to direct the vote:
See the response(s) to Item 6 on the
attached cover page(s).
 - (iii) Sole power to dispose or to direct the
disposition of:
See the response(s) to Item 7 on the
attached cover page(s).
 - (iv) Shared power to dispose or to direct the
disposition of:
See the response(s) to Item 8 on the
attached cover page(s).
-

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact
that as of the date hereof the reporting person has ceased
to be the beneficial owner of more than five percent of the
class of securities, check the following

[]

Item 6. Ownership of More than Five Percent on Behalf of
Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the
Parent Holding Company.

See Exhibit A.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my
knowledge and belief, the securities referred to
above were acquired and are held in the ordinary
course of business and were not acquired and are

not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 11, 2023

By : Ramya Rao

Title: Vice President

INDEX TO EXHIBITS

Exhibit A Item 7 Information
Exhibit B Joint Filing Agreement

EXHIBIT A

The securities being reported on by Barclays PLC, as a parent holding company, are owned, or may be deemed to be beneficially owned, by Barclays Bank PLC, a non-US banking institution registered with the Financial Conduct Authority authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom. Barclays Bank PLC, is a wholly-owned subsidiary of Barclays PLC.

EXHIBIT B

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(k) (1) under the Securities Exchange Act of 1934, as amended, on behalf of each such person.

Dated: January 11, 2023

BARCLAYS PLC

By : Ramya Rao

Title: Vice President

Barclays Bank PLC

By : Ramya Rao

Title: Vice President

Barclays Capital Inc.

By : Ramya Rao

Title: Vice President

Barclays Capital Securities Ltd

By : Ramya Rao

Title: Vice President